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Abstract
Background: The 2009 pandemic H1N1 (A(H1N1)pdm09) influenza A virus (IAV) has 
replaced the previous seasonal H1N1 strain in humans and continues to circulate 
worldwide. The comparative performance of inactivated A(H1N1)pdm09 influenza 
vaccines remains of considerable interest. The objective of this study was to evaluate 
the efficacy of two licensed A(H1N1)pdm09 inactivated vaccines (AS03B adjuvanted 
split virion Pandemrix from GlaxoSmithKline and referred here as (V1) and non-adju-
vanted whole virion Celvapan from Baxter and referred here as (V2)) in ferrets as a 
pre-clinical model for human disease intervention.
Methods: Naïve ferrets were divided into two groups (V1 and V2) and immunised 
intramuscularly with two different A/California/07/2009-derived inactivated vac-
cines, V1 administered in a single dose and V2 administered in 2 doses separated by 
21 days. Six weeks after the first immunisation, vaccinated animals and a non-vac-
cinated control (NVC) group were intra-nasally challenged with 106.5 TCID50 of the 
isolate A/England/195/2009 A(H1N1)pdm09 with 99.1% amino acid identity to the 
vaccine strain. Clinical signs, lung histopathology, viral quantification and antibody 
responses were evaluated.
Results and Conclusions: Results revealed important qualitative differences in the 
performance of both inactivated vaccines in relation to protection against challenge 
with a comparable virus in a naive animal (ferret) model of human disease. Vaccine V1 
limited and controlled viral shedding and reduced lower respiratory tract infection. 
In contrast, vaccine V2 did not control infection and animals showed sustained viral 
shedding and delayed lower respiratory infection, resulting in pulmonary lesions, 
suggesting lower efficacy of V2 vaccine.
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1  | INTRODUC TION
Since its emergence, the A(H1N1)pdm09 influenza A virus (IAV) 
has become established worldwide in the human population and 
replaced the previous seasonal human H1N1 viruses.1 Head-
to-head comparisons of the extent to which diverse influenza 
vaccines prevent viral infection and disease in biological model 
systems are infrequent, but important to generate evidence 
relevant to, reported variations of effectiveness between influ-
enza vaccines deployed in the field.2,3 Three vaccine platforms 
are currently licensed for influenza prevention in humans: in-
activated subunit or whole virion vaccines, live attenuated and 
recombinant haemagglutinin (HA) protein. For inactivated IAV 
vaccines, reference strains are produced with the HA and neur-
aminidase (NA) genes derived from the most recently circulat-
ing strains, as recommended by the World Health Organization 
(WHO) Influenza Virus Vaccine Selection Committee, and the in-
ternal protein genes from a laboratory influenza strain adapted 
to grow in eggs.4 Inactivated vaccines primarily induce serum 
antibodies against the HA, which are capable of strain-specific 
neutralisation of influenza viral particles thus protecting from 
infection. In order to increase the production of these antibod-
ies, some licensed inactivated vaccines also include adjuvant, 
such as AS03 or MF59,5 which enhance immunity against the 
target antigen.
This study evaluates the efficacy of two A(H1N1)pdm09-derived 
inactivated vaccines, one adjuvanted Pandemrix (AS03B adjuvanted 
split virion vaccine) referred hereafter as V1 and one non-adjuvanted 
Celvapan (non-adjuvanted whole virion vaccine) referred hereaf-
ter as V2 at the human dose and schedule6 in the ferret (Mustela 
putorius furo) model after challenge with a A(H1N1)pdm09 strain. 
Vaccines used in this study were selected and compared as part of 
pandemic vaccination stockpiling policy in preparedness for subse-
quent influenza pandemic waves. The rationale of the study was to 
provide comparative data on the immunogenicity and protection 
in animal models after viral challenge using the human vaccination 
schedule in clinical trials. The aim of the study was to evaluate vac-
cine individual efficacy against a single homologous strain challenge 
as opposed to the efficacy conferred by seasonal multivalent vac-
cine immunogens, comparing the parameters of clinical signs, viral 
shedding, histopathology and viral antigen distribution, viral tissue 
load and serology relating these data to performance of these vac-
cines in humans.
2  | MATERIAL S AND METHODS
2.1 | Virus isolation and propagation
The challenge strain was A/England/195/2009 (E195, GQ166661) 
and hereafter referred to as (A/Eng) A(H1N1)pdm09. The virus was 
isolated by Madin–Darby Canine Kidney (MDCK) cell culture, plaque 
purified three times and verified by whole genome sequencing.7
2.2 | Vaccines
Both vaccines used in this study were based on the prototype 
A(H1N1)pdm09 strain A/California/07/2009 (A/Cal). Vaccine 1 (V1) 
was a split inactivated influenza virus vaccine constructed from the v-
like strain antigen (New York Medical College x-179A), generated by 
classical re-assortment in embryonated eggs consisting of a 0.25 mL 
suspension containing 3.75 µg of HA mixed with 0.25 mL emulsion 
of AS03B adjuvant and the latter composed of squalene (10.69 mg), 
DL-α-tocopherol (11.86 mg) and polysorbate 80 (4.86 mg). Vaccine 2 
(V2) consisted of a whole virion influenza vaccine, containing 7.5 µg 
inactivated HA of A/Cal virus propagated in Vero cells.
2.3 | Ferret immunisation
Animal experiments were approved by the APHA ethics committee 
and conform to the ARRIVE guidelines and UK legislation under the 
Animals (Scientific Procedures) Act 1986 Amendment Regulations 
(SI 2012/3039). Forty-three naïve male ferrets of approximately 
8 months of age were selected from a stable, purposely bred colony 
and received a subcutaneous Biothermal microchip (digital angel) 
implant for identification and temperature monitoring. Ferrets 
were shown to be seronegative for IAV antibodies using haemag-
glutination inhibition (HI) assay to the temporally relevant circulat-
ing seasonal human vaccine strains: A/Brisbane/59/2007 (H1N1), 
A/Uruguay/716/2007 (H3N2), B/Brisbane/60/2008 (B/ Victoria 
lineage), A/England/195/2009, and A/California/7/2009 (A(H1N1)
pdm09) and pan-influenza A ELISA. The absence of influenza A in-
fection was confirmed by verifying that no influenza A virus RNA 
could be detected in nasal wash samples.
Ferrets were randomly assigned to different experimental 
groups (Figure 1). Two experimental groups of 15 animals (vaccine 
immunised) and one non-vaccinated control group of 10 animals 
(NVC) were challenged with 106.5 TCID50 A/Eng/195 grown in 
MDCK cell culture. Animals in group V1 were immunised with vac-
cine 1 (0.25 mL of antigen and 0.25 mL of the AS03B adjuvant, mixed 
immediately before immunisation) in a single dose. The second vac-
cinated group, V2, was immunised twice with 0.5 mL of the vaccine 
2, with a 21-day interval, mimicking human schedule. The NVC group 
received a single dose of 0.5 mL of PBS. A fourth group of three 
animals received AS03B adjuvant only (0.25 mL AS03B mixed with 
0.25 mL PBS). All inoculates were administered intramuscularly in 
the left hind limb. Blood samples were taken under anaesthesia on 0, 
7, 11, 14, 18, 21, 28 and 34 days post-vaccination (dpv).
2.4 | Ferret experimental infection and clinical signs
Six weeks after the initial immunisation, animals in all groups were 
challenged with 106.5 TCID50 of A/Eng virus in a total of 0.4 mL (0.2 mL 
per nostril). Ferrets were monitored daily for changes in temperature 
and body weight. Subsets of animals (5 per group) were humanely 
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killed on 3, 5 and 14 days post-infection (dpi) by intravenous injec-
tion of sodium pentobarbital overdose injection, under anaesthesia 
with ketamine and medetomidine, and a series of tissues (brain, olfac-
tory bulb, thoracic trachea, nasal turbinate and lung) collected. On 
alternate days post-challenge (1-14), nasal washes and rectal swabs 
were also collected under anaesthesia. All samples were assayed for 
the detection of influenza A M gene using specific RT-qPCR.8 Nasal 
turbinate, trachea and lung tissues were collected for histopathology. 
Serum antibody responses were evaluated by haemagglutination in-
hibition (HI) assays at −8 dpi/34 dpv, and at 3, 5 and 14 dpi as previ-
ously described.9
2.5 | Histopathology
Samples of nasal turbinate, trachea and each of the right lung lobes 
were collected from ferrets humanely killed at 3 and 5 dpi and fixed in 
10% neutral-buffered formalin for a minimum of 5 days. During post-
mortem examination, nasal turbinate samples were collected by care-
fully removing the nasal concha from the ethmoid and maxillary bone 
and the nasal septum with a thin scalpel (ie number 11 surgical scal-
pel blade) after sagittal sectioning of the cranium; no decalcification 
methods were used. Tissues were routinely processed and embedded 
in paraffin wax, sectioned at 4 µm, and stained with haematoxylin and 
eosin (HE) for examination under light microscopy by a veterinary pa-
thologist. In addition, a semi-quantitative assessment of IAV-associated 
microscopic lesions in the lungs was performed separately in cross sec-
tions of the right cranial, middle and caudal pulmonary lobes for each 
animal. The HE lesion scoring was graded on the basis of severity as 
previously described.10 The mean count for all three lobes was used for 
the final histopathological score for each animal.
2.6 | Viral detection and quantification
2.6.1 | RT-qPCR
Viral RNA from nasal washes, rectal swabs and tissue homogen-
ates was extracted according to published methods.8 The A(H1N1)
pdm09 viral matrix gene RT-PCR was performed as described previ-
ously.11 Ct values obtained from clinical specimens were converted 
to relative equivalent units (REUs) by correlation with a standard line 
produced using a 10-fold dilution series of RNA prepared from the 
same stock as the inoculum with known titre.
F I G U R E  1   Experimental immunisation and challenge diagram. Ferrets were divided into groups and were either not vaccinated (NVC, 
n = 10) or were vaccinated with vaccines V1 or V2 (n = 15 for each vaccine) before being challenged. A further groups of 3 ferrets received 
AS03 adjuvant alone
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2.6.2 | Immunohistochemistry (IHC)
Detection of IAV nucleoprotein (NP) by IHC was performed as de-
scribed12 on nasal turbinates, trachea and lungs. Briefly, sections 
for IHC were dewaxed and endogenous peroxidase activity was 
quenched with a methanol/hydrogen peroxide block for 15 minutes 
and treated with Protease XXIV for 10 minutes at room temperature. 
Primary antibody cross-reactivity with tissue constituents was pre-
vented using a normal immune serum block. Samples were incubated 
with an anti-Influenza A nucleoprotein primary mouse monoclonal an-
tibody (Statens Serum Institut) for 1 hour and Dako ENVISION™ pol-
ymer for 30 minutes at room temperature. The immunohistochemical 
signal was visualised using 3,3-diaminobenzidine (Sigma-Aldrich) and 
counterstained in Mayer's haematoxylin (Surgipath). Viral NP antigen 
was assessed in all tissues, and levels were semi-quantitatively evalu-
ated in the lungs using a modified method.10,13 Alveolar and bron-
chial/bronchiolar NP-positive cell counts were calculated separately. 
The mean of the total scores for both bronchial parameters across 
two tissue sections of each lung lobe was calculated for each animal.
2.7 | Serological analysis
Ferret sera were assayed using A(H1N1)pdm09 influenza A antigens 
and turkey red blood cells (RBC).9 Longitudinal experimental serum 
samples were analysed during the study by HI using the homologous 
A/England/195/2009 strain and pan-influenza A ELISA in order to 
assess vaccine immunogenicity post-vaccination and to assess recall 
response post-challenge.
2.8 | Statistical analysis
Graphics and statistical differences between groups were analysed 




Two ferrets of thirty (one given V1 and one given V2 vaccine) devel-
oped a small lump at the site of injection on the day following vac-
cination, which remained for 2 days. Ferrets did not show any signs 
of pain or discomfort.
3.1.2 | Clinical signs post-challenge
A significant transient elevation in temperature was observed in 
vaccinated animals on 2 dpi in comparison with the NVC group 
(P < .0001) and in NVC in comparison with vaccinated groups 
(P < .01), at 3 dpi (Figure 2A). The variation in body temperature was 
consistent with that observed for viral shedding level (Figure 2C).
Following infection, all infected ferrets lost over 2.5% of their 
total body weight (Figure 2A) at 1 dpi. The NVC group had a sig-
nificant (P < .001) weight loss percentage in comparison with vac-
cinated groups (Figure 2B), at 2 dpi. The V2 group showed lower 
body weight in comparison with the V1 and NVC groups at 4 and 
5 dpi. From 6 dpi, animals in all groups present a steady weight gain 
percentage.
3.2 | Viral shedding
Nasal shedding data demonstrated that virus replication (RNA) was 
significantly higher in the V1 group in comparison with V2 (P < .05) 
and NVC (P < .001) at 1 dpi. In contrast, the V1 group showed sig-
nificantly reduced viral RNA levels than the NVC and V2 groups at 2 
(P < .0001) and 6 dpi (P < .001). At 12 dpi, the V1 group presented 
significantly reduced viral RNA levels than the NVC group  (P < .01) 
and the V2 group (P < .0001). Significantly higher viral RNA levels 
were detected in the nasal wash of the V2 group in comparison with 
the NVC and V1 groups at 4 dpi (P < .0001), and in comparison to the 
V1 group at 10 dpi (P < .05) (Figure 2C).
Low levels of rectal shedding (RNA) were detected in the NVC 
group and V2 groups but no RNA was detected in the V1 group fol-
lowing challenge. The overall mean rectal shedding in the V1 group 
was significantly reduced in comparison with the NVC and V2 groups 
at 2, 4 and 6 dpi (P < .05). In addition, significantly higher viral RNA 
levels were observed in the V2 group in comparison with the NVC 
and V1 groups at 10 dpi (P < .001) (Figure 2D).
3.3 | Histopathology
Histopathological examination of the nasal turbinate and trachea, 
as well as, histopathological scoring of the lungs were performed 
at 3 and 5 dpi. NVC animals showed more severe histopathologi-
cal lesions in the upper respiratory tract (URT) (nasal turbinate and 
trachea), than both vaccinated groups at 3 dpi. V1 group ferrets 
showed only mild lesions in nasal turbinate and trachea at 3 dpi, and 
no substantial lesions were observed at 5 dpi. In contrast, ferrets be-
longing to the V2 group showed slightly increased severity of lesions 
than the NVC and the V1 groups at 5 dpi. More substantial lesions 
observed in the nasal turbinate and trachea were consistent with a 
moderate fibrinosuppurative rhinitis and a moderate lymphoplasma-
cytic tracheitis, respectively (Figure 3).
In the lungs, ferrets in the V1 group showed significantly (P < .05) 
lower histopathological scores at both 3 and 5 dpi when compared 
to the NVC group, and when compared to the V2 group (P < .05) 
(Figure 4A) at 5 dpi. These results mirrored the histopathology and 
IHC at 3 dpi, where no or minimal histopathological lesions were ob-
served in V1. Lesions were characterised by a minimal bronchiolitis 
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(star) with the presence of no or minimal lymphocyte and macro-
phage infiltrates (Figure 5). NVC and V2 groups showed similar his-
topathological scores to each other at 3 dpi. Highest scores were 
observed at 5 dpi in V2-vaccinated animals (Figure 4A), showing 
increased severity of lesions in comparison with the V1 and NVC 
groups. More substantial histopathological lesions in V2 were con-
sistent with a moderate bronchointerstitial pneumonia. Lesions were 
characterised by variable bronchiolar and alveolar epithelial necro-
sis, lymphoplasmacytic infiltration, with mucus and cell debris filling 
the bronchioles (arrow) and/or the alveoli (arrowhead) (Figure 5). 
Two animals per time point (3 and 5 dpi) showed interstitial lung le-
sions in the V2 group, while only one ferret per time point showed 
the same lesions in the NVC group.
3.4 | Viral antigen detection and quantification
Viral detection by IHC was performed in nasal turbinate, trachea 
and lung fixed tissues at 3 and 5 dpi. In general, viral antigen was 
observed in the nucleus and cytoplasm of respiratory and olfactory 
epithelial cells (arrowhead) and glandular cells (arrow) in the nasal 
turbinates and trachea (Figure 3). Stronger IAV IHC immunolabelling 
was observed in the nasal turbinates of the V2 group, followed by 
the NVC and V1 groups, at both 3 and 5 dpi. In the trachea, the NVC 
group showed the strongest IAV antigen immunolabelling, followed 
by the V2 group, at 5 dpi.
In the lungs, viral antigen was observed in bronchial/bronchiolar 
epithelial (arrow) and glandular cells (arrowhead), alveolar epithelial 
F I G U R E  2   Clinical signs. Mean temperature (A) and weight (B) for each day post-infection (DPI) are shown for groups V1 (V1 vaccine), 
V2 (V2 vaccine) and NVC (non-vaccinated control). The NVC group showed significantly lower (P < .0001) and higher temperature (P < .01) 
than the vaccinated groups (V1 and V2) at 2 and 3 dpi, respectively. The NVC group showed significantly (P < .001) lower weight percentage 
in comparison with vaccinated groups (B), at 2 dpi. Viral RNA detection and quantification by RT-qPCR in nasal washes (C). The V1 group 
showed significantly higher viral loads at 1 dpi in comparison with the V2 and NVC groups (P < .05) and significantly lower viral loads than 
the V2 and NVC groups at 2, 6 (P < .0001) and 12 dpi (P < .01). The V2 group showed significantly higher viral loads in comparison with both 
the NVC and the V1 groups at 4 dpi (P < .0001) than the V1 group at 10 dpi (P < .05). Viral RNA detection and quantification by RT-qPCR in 
rectal swabs (D). V1 presented with significantly lower viral loads than the V2 and NVC groups at 2 (P < .0001), 4 (P < .001) and 6 (P < .05) 
dpi. The V2 group showed significantly higher viral loads than the NVC and the V1 groups at 10 dpi (P < .001). RT-qPCR graphs show 
relative equivalent units (REUs). The assay limit of RNA detection is reached at an REU of 1. All samples below the assay limit are shown 
as 1. Mean ± standard error of the mean (SEM). Statistical analysis was carried out using two-way analysis of variance. Differences were 
considered statistically significant at P < .05, P < .01, P < .001 and P < .0001, and represented as *, **, *** or ****, respectively
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cells (star) and few macrophages of animals belonging to the V2 and 
NVC groups (Figure 5). Semi-quantitative evaluation of influenza 
virus nucleoprotein-positive cells in the lungs showed that tissues 
from the V1 group had significantly lower (P < .05) IHC-positive 
scores in airway (bronchial/bronchiolar) (Figure 4B) and alveolar 
areas (Figure 4C) at 3 dpi in comparison with the NVC and V2 groups, 
but no differences were observed between the V2 and NVC groups. 
At 5 dpi, the V1 group presented significant lower positive scores 
in comparison with the V2 and NVC groups in the airways (bron-
chial/bronchiolar areas) (Figure 4B), while no significant differences 
were observed between groups in alveolar areas at this time point 
(Figure 4C).
F I G U R E  3   Histopathological lesions and immunohistochemical detection of influenza virus nucleoprotein in nasal turbinates and trachea 
at 5 dpi. Haematoxylin and eosin (HE) staining of tissues and immunohistochemical (IHC) detection of influenza virus nucleoprotein (NP) 
showed a moderate fibrinosuppurative rhinitis and lymphoplasmacytic tracheitis observed in group V2, characterised by increased number 
of inflammatory infiltrates and epithelial damage than the V1 (vaccine 1) group and the non-vaccinated control (NVC) group. Viral NP 
immunolabelling observed in respiratory and olfactory epithelium (arrowhead) and glandular epithelium (arrow) of the trachea and nasal 
turbinates in all groups. Magnification 10x
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3.5 | Tissue viral load
Following challenge, brain, olfactory bulb, nasal turbinate, trachea 
and lung were collected at 3 and 5 dpi (Figure 6A and B) and viral 
load was assessed by viral RNA quantification by RT-qPCR. At 3 dpi, 
no detectable viral RNA levels were detected in the brain of animals 
belonging to the vaccinated groups. Olfactory bulb viral RNA levels 
were lower in vaccinated groups than in the NVC control group. At 
5 dpi, all three groups showed similar negligible viral loads in the 
brain and V2 and NVC showed similar viral replication in the olfac-
tory bulb, which were higher in comparison with the V1 group.
In thoracic tissues, the V1 group showed the lowest viral load of 
the three groups at both 3 and 5 dpi, especially in comparison with 
NVC. In general, the V2 vaccine showed lower viral loads than the 
NVC group at 3 dpi. However, at 5 dpi, V2 and NVC showed similar 
viral load levels in the upper and lower respiratory tract. In the V1 
group, there was significant (P < .005) control of viral load in the 
turbinates, at 5 dpi, in comparison with the NVC group. In contrast, 
the V2 group showed similar viral loads to that of the NVC group at 
5 dpi. The reduction of viral load by V1 was evident (P < .001) in both 
the URT (trachea and turbinates) and the lung. V2 had less effect 
than V1 but, nonetheless, was able to significantly reduce viral load 
(P < .001) in both the URT (NS) and the lung.
3.6 | Serology
During immunisation, V1-immunised ferrets showed HI antibody ti-
tres ranging from 16 up to 1024, while V2-immunised ferrets and 
AS03 adjuvant only group presented with negative antibody titres 
of <8 over the same time period (1 week to 34 dpv) (Table 1). Micro-
neutralisation titres (MNT) were similar, for V1 ranged from 3.3 to 
383.2, while V2 MNT titres were only detectable late post-immuni-
sation (DPV 28-24) at 10-13 titres (data not shown).
F I G U R E  4   Pulmonary histological scores (A). Mean histopathological score of lung lobes. Mean ± SEM is shown. The V1 group showed 
significantly lower histopathological scores than the NVC (P < .01 and .05) and the V2 groups (P < .05 and .001), at 3 and 5 dpi, respectively. 
Influenza A virus antigen immunolabelling score in airway (bronchial/bronchiolar) (B) and alveolar (C) areas at 3 and 5 dpi. The V1 group 
had significantly lower nucleoprotein (NP) immunolabelling scores than the NVC group in airway (P < .01) and alveolar areas (P < .05) at 
3 dpi. The V1 group also showed significantly lower immunolabelling scores than the NVC (P < .01) and the V2 (P < .01) groups in airway 
areas at 5 dpi. Mean ± SEM of NP-positive immunolabelling per lung lobe. Statistical analysis was carried out using one-way analysis of 
variance. Differences were considered statistically significant at P < .05, P < .01, P < .001 and P < .0001, and represented as *, **, *** or ****, 
respectively
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Following the immunisation, 8 days prior to challenge and 34 dpv, 
homologous antibodies were detected in the V1 group. These titres 
were significantly higher than those in the V2 group, which showed 
very low levels (P < .001) (Figure 6C). Post-challenge, antibody lev-
els against A/Eng increased at 3 and 5 dpi, with V1 titres remaining 
significantly higher than V2 titres (P < .005). No antibodies were 
detected at 3 or 5 dpi in the NVC group. At 14 dpi, high levels of ho-
mologous antibodies were detected in all groups (Figure 6C), with no 
statistically significant differences were detected between groups. 
The anamnestic response in the V1 group saw a ~50-fold increase in 
F I G U R E  5   Lung histopathological lesions and viral antigen immunohistochemistry (IHC) in airway and alveolar areas at 3 days post-
infection (dpi). Haematoxylin and eosin (HE) stain revealed that lesions ranged from absent (star) to minimal bronchiolitis in the vaccine 1 
(V1) group to more severe lesions observed in the vaccine 2 (V2) group and the non-vaccinated control (NVC) group. Lesions in the V2 and 
NVC groups evaluated in HE stain were similar and were consistent with a mild to moderate bronchointerstitial pneumonia characterised 
by airway and alveolar epithelial necrosis accompanied by inflammatory infiltrates filling the alveolar spaces (arrowhead) and airways. 
Magnification 20×. Increased numbers of viral nucleoprotein immunolabelled cells were observed by IHC in the V2 and NVC groups in 
comparison with the V1 group. Positive immunolabelling by IHC was observed in the airway (arrow), glandular epithelium (arrowhead) and 
the alveolar epithelium (star) of NVC and V2 group ferrets. Magnification 20x
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F I G U R E  6   Tissue distribution of influenza virus at 3 dpi (A) and 5 dpi (B). Mean ± standard error of the mean (SEM). Viral RNA 
quantification by RT-qPCR on tissue homogenates. The V1 group showed significantly lower viral loads than the NVC and V2 groups in 
the trachea (P < .01 and .05) and lung (P < .001 and .01) at 3 dpi. The V1 group showed significantly lower viral load than the NVC and 
V2 groups in nasal turbinates (P < .001), trachea (P < .0001(NVC) and P < .001(V2)) and lung (P < .001(NVC) and P < .01(V2)) at 5 dpi. 
Haemagglutination inhibition (HI) antibody titre (C). Pre- and post-challenge geometric mean (GM) HI antibody response against A/Eng virus. 
Geometric mean and geometric standard deviation (SD). The V1 vaccine showed significantly higher HI titres than the V2 group at −8 dpi 
(P < .0001) and, than both the V2 and the NVC groups at 3 (P < .05 and 5 dpi (P < .05). Statistical analysis was carried out using Student's t 
test analysis for testing the differences between HI titres at −8 dpi/34 dpv between vaccinated groups and one-way analysis of variance for 
the rest of all variables at each time point post-infection. Differences were considered statistically significant at P < .05, P < .01, P < .001 





0 7 11 14 18 21 28 34
Boost
V1 vaccine 1 0 16 128 256 256 32 32 128
2 0 256 512 512 1024 512 512 512
3 0 32 256 512 NS 128 128 256
V2 vaccine 1 0 <8 <8 <8 NS <8 <8 <8
2 0 <8 <8 <8 <8 <8 <8 <8
3 0 <8 <8 <8 <8 <8 <8 <8
AS03 Adjuvant 1 0 <8 <8 <8 NS NS NS <8
2 0 <8 <8 <8 NS <8 NS <8
3 0 <8 <8 <8 NS <8 <8 NS
NVC 1 0 <8 <8 <8 NS NS NS <8
Abbreviations: NS, no sample; NVC, non-vaccinated control.
TA B L E  1   Haemagglutination inhibition 
(HI) antibody titres of immunised ferrets 
during vaccination
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titres from 22 days post-vaccine to 14 days post-challenge, whereas 
for V2 this was ~500-fold increase; both vaccines attained approxi-
mately the same final titre at 14 dpi (Figure 6C).
4  | DISCUSSION
Human vaccines tested in this study using the ferret model showed 
differences in their efficacy against diverse parameters of A(H1N1)
pdm09 infection resulting in different infection outcomes. The adju-
vanted inactivated split virion vaccine (V1) limited and controlled viral 
shedding and replication outside the airway and clearly reduced res-
piratory tract infection. In contrast, the non-adjuvanted inactivated 
whole virion vaccine (V2) appeared to delay respiratory tract infec-
tion with a slight reduction of viral shedding but resulting in similar 
lung lesions in comparison with the NVC group and much less marked 
effect on virus replication in tissues outside the respiratory tract.
The HI assay is commonly used to measure anti-HA antibodies 
for vaccine evaluations, and HI antibody titres ≥ 40 have tradition-
ally been considered to be protective against infection with a ho-
mologous influenza A strain.14,15 In this study, the immunogenicity of 
the two vaccines was significantly different. A single dose of 3.75 µg 
AS03B adjuvanted subunit vaccine (V1) was more immunogenic 
than two doses of 7.5 µg whole virus vaccine (V2) as per vaccine 
dosing guidelines in humans. In the V2 group, vaccination did not 
elicit a high anti-HA antibody response during the 34 days post-im-
munisation, while the V1 group produced detectable titres from 
1 week post-immunisation onwards; results were similar for the im-
munisation and challenge study, and for virus neutralisation assays. 
The observed differences in vaccine immunogenicity in the ferret 
model are consistent with the observed superiority of the immune 
response to V1 vaccines in paediatric head-to-head comparison clin-
ical studies in the UK.6
Previous studies have shown that the presence of HI antibody 
titres is often low at early stages post-infection in individuals pre-
viously vaccinated with A(H1N1)pdm09 vaccine.16 However, the 
presence of cross-reactive antibodies and the secondary antibody 
response from memory B cells play an important role in the control 
of viral replication during this early phase of infection. In this study, 
vaccines tested provided different protection levels against high-
dose virus challenge in the naive ferret model. Differences between 
the vaccines were noted using clinical, pathological and virological 
end points, where the adjuvanted inactivated vaccine V1 showed 
higher efficacy and better protection than the non-adjuvanted V2 
vaccine.
A substantial antibody response was seen following virus chal-
lenge in animals immunised with V1 vaccine between days 3 and 
14, whereas this was not observed until day 8-14 post-challenge in 
ferrets immunised with the V2 vaccine. In addition, the V2 group 
showed higher temperature after 8 dpi in comparison with the V1 
group that was associated with higher viral shedding from the rec-
tal and nasal swabs at the same time points, and more severe lung 
pathology.
The V1 group showed limited spread of viral antigen in the lungs 
consistent with the minimal to mild histopathological pulmonary le-
sions observed. These results confirm the higher level of protection 
achieved by the V1 vaccine against viral replication in comparison 
with other inactivated vaccines, as reported previously.17-19 V2 and 
NVC showed similar histopathology in lungs following challenge. 
These lesions were characterised by a moderate lymphoplasmacytic 
bronchointerstitial pneumonia that was associated with the pres-
ence of higher IAV antigen counts in alveolar areas. These results 
are in accordance with previous studies where more severe respira-
tory outcomes after A(H1N1)pdm09 infection in ferrets and humans 
were related to the spread of viral antigen to alveolar areas and the 
associated inflammatory response.10,20
At 5 dpi, the V2 group showed similar to slightly increased se-
verity on lung histopathological lesions compared to the NVC group, 
in accordance with the presence of similar RNA viral levels in the 
lungs and other organs between these groups. These results may 
indicate that viral replication was only delayed but not controlled by 
V2 vaccine, resulting in lung pathology. It is known that susceptibility 
to IAV-associated lung pathology in humans is partially determined 
by multiple host factor characteristics, which include prior immunity, 
co-morbidities and host genetic characteristics.21,22 Consequently, 
basal immune alterations, and/or the presence of a previous inflam-
matory state, may impact upon the normal development of specific 
immune response against A(H1N1)pdm09, and increase the risk of 
developing poor outcome of infection or antibody adverse immune 
reactions. Therefore, the use of vaccines which modulate but do not 
control/prevent infection may pose a substantial health threat for 
their use in higher risk individuals.
Non-neutralising antibodies against IAV can have either protec-
tive, neutral non-protective or detrimental effects.23 Detrimental ef-
fects produced by non-neutralising antibodies have been suggested 
to be related to poor outcomes of various viruses, including A(H1N1)
pdm09.24,25 In addition, a delay in viral clearance rather than a high 
viral load in the respiratory tract has been associated with severe 
disease in human patients, which may reflect the delay of infection 
parameters observed in the V2 group in this study. 23
V2 group lung lesions at 5 dpi were mostly associated with viral 
antigen presence in alveolar areas, a consequence that is most likely 
related to poor induction of specific A(H1N1)pdm09 antibodies 
during immunisation in this group and to the detrimental inflamma-
tory cellular responses as described elsewhere.10,26,27 However, the 
V2 group showed some antibody response during infection, that was 
higher than the non-vaccinated challenge group, and lower viral an-
tigen presence than the NVC control group by IHC, indicating some 
level of priming of the antibody response induced by the non-adju-
vanted vaccine.
In conclusion, in the ferret model of human influenza, the AS03 
adjuvanted inactivated vaccine V1 provided better protection 
against clinical disease following A(H1N1)pdm09 infection than 
the non-adjuvanted inactivated V2 vaccine, which had a lower an-
tibody response, higher viral load and clinical disease comparable to 
non-vaccinated ferrets. These results identify the need for improved 
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knowledge of head-to-head comparisons of vaccine performance 
in humans at the population level, and the usefulness of biologi-
cal model systems for teasing out aspects of adaptive immune re-
sponses assisting with potential improvements of vaccine design and 
delivery.
ACKNOWLEDG EMENTS
This project was accomplished by the Pandemic Influenza Vaccine 
Evaluation Consortium (PIVEC), which was established as a consor-
tium of HPA/PHE (Colindale and NIBSC) and VLA/AHVLA/APHA. 
The members would like to thank Elizabeth Millar and John Wood 
for their invaluable input at the outset of the project, funded by 
NIHR—Department of Health Policy Research Programme Central 
Commissioning Facility (PRP CCF) grant number 019/0030. APHA 
core staff are supported by DEFRA (England) and the devolved 
administrations in Scotland and Wales. The authors are grateful to 
Lorenzo Rapisarda (Named Veterinary Surgeon); Rachel Baker, Kevin 
Furey, Paul Sharp, Stuart Smith and Marie Rickard (Animal Services 
Unit, APHA); Kate Guilfoyle, Rose Leahy, Pauline Lloyd and Sarah 
Skeldon (NIBSC); Nichola Goddard (HPA); and Virag Patel (Statistical 
Analysis, APHA) for their service and advice.
CONFLIC T OF INTERE S T
All authors declare that they have no conflict of interest.
AUTHOR CONTRIBUTION
Beatriz Vidana: Data curation (equal); Formal analysis (equal); 
Investigation (equal); Methodology (equal); Software (lead); 
Visualization (lead); Writing-original draft (lead); Writing-review 
& editing (lead). Sharon M. Brookes: Funding acquisition (equal); 
Investigation (equal); Methodology (equal); Project administration 
(equal); Supervision (lead); Validation (equal); Writing-original draft 
(equal); Writing-review & editing (lead). Helen Everett: Data cura-
tion (equal); Formal analysis (supporting); Methodology (supporting); 
Supervision (equal); Writing-original draft (supporting); Writing-
review & editing (supporting). Fanny Allen: Formal analysis (equal); 
Investigation (equal); Resources (equal); Writing-review & editing (sup-
porting). Alejandro Nuñez: Investigation (supporting); Methodology 
(equal); Supervision (supporting); Writing-original draft (supporting); 
Writing-review & editing (supporting). Othmar G Engelhardt: Data 
curation (supporting); Formal analysis (supporting); Supervision (sup-
porting); Validation (supporting); Writing-original draft (supporting); 
Writing-review & editing (supporting). Diane Major: Resources (sup-
porting); Supervision (supporting); Writing-review & editing (sup-
porting). katja hoschler: Formal analysis (supporting); Methodology 
(supporting); Resources (supporting); Writing-review & editing (sup-
porting). Ian Brown: Formal analysis (supporting); Project administra-
tion (supporting); Resources (supporting); Supervision (supporting); 
Validation (supporting); Writing-review & editing (supporting). Maria 
Zambon: Conceptualization (lead); Data curation (equal); Formal anal-
ysis (lead); Funding acquisition (lead); Project administration (lead); 
Resources (equal); Supervision (lead); Writing-original draft (equal); 
Writing-review & editing (lead).
ORCID
Beatriz Vidaña  https://orcid.org/0000-0003-1724-1006 
Othmar Engelhardt  https://orcid.org/0000-0002-0465-9908 
R E FE R E N C E S
 1. WHO. Influenza (Seasonal). Geneva: World Health Organisation. 
https://www.who.int/news-room/fact-sheet s/detai l/influ en-
za-(seaso nal). Published 2019. Accessed.
 2. Lansbury LE, Smith S, Beyer W, et al. Effectiveness of 2009 pan-
demic influenza A(H1N1) vaccines: a systematic review and me-
ta-analysis. Vaccine. 2017;35(16):1996-2006.
 3. DeMarcus L, Shoubaki L, Federinko S. Comparing influenza vac-
cine effectiveness between cell-derived and egg-derived vaccines, 
2017–2018 influenza season. Vaccine. 2019;37(30):4015-4021.
 4. WHO. Recommended Composition of Influenza Virus Vaccines for Use 
in the 2019–2020 Northern Hemisphere Influenza Season. Geneva: 
World Health Organisation. (https://www.who.int/influ enza/vacci 
nes/virus/ recom menda tions/ 2019_20_north/ en/) Published 2019. 
Accessed.
 5. Atmar RL, Keitel WA. Adjuvants for pandemic influenza vaccines. 
Curr Top Microbiol Immunol. 2009;333:323-344.
 6. Waddington CS, Walker WT, Oeser C, et al. Safety and immu-
nogenicity of AS03B adjuvanted split virion versus non-adju-
vanted whole virion H1N1 influenza vaccine in UK children aged 
6 months-12 years: open label, randomised, parallel group, multi-
centre study. BMJ. 2010;340:c2649.
 7. Baillie GJ, Galiano M, Agapow PM, et al. Evolutionary dynamics of 
local pandemic H1N1/2009 influenza virus lineages revealed by 
whole-genome analysis. J Virol. 2012;86(1):11-18.
 8. Slomka MJ, Densham AL, Coward VJ, et al. Real time reverse tran-
scription (RRT)-polymerase chain reaction (PCR) methods for de-
tection of pandemic (H1N1) 2009 influenza virus and European 
swine influenza A virus infections in pigs. Influenza Other Respir 
Viruses. 2010;4(5):277-293.
 9. OiE. Swine Influenza. In Manual of diagnostic tests and vaccines for 
terrestrial animals. 1, 8th ed, Paris: World Organisation of Animal 
Health). 2018.
 10. Vidana B, Martinez J, Martinez-Orellana P, et al. Heterogeneous 
pathological outcomes after experimental pH1N1 influenza infec-
tion in ferrets correlate with viral replication and host immune re-
sponses in the lung. Vet Res. 2014;45(1):85.
 11. Spackman E, Senne DA, Myers TJ, et al. Development of a re-
al-time reverse transcriptase PCR assay for type A influenza virus 
and the avian H5 and H7 hemagglutinin subtypes. J Clin Microbiol. 
2002;40(9):3256-3260.
 12. Londt BZ, Brookes SM, Nash BJ, Nunez A, Stagg DA, Brown IH. 
The infectivity of pandemic 2009 H1N1 and avian influenza viruses 
for pigs: an assessment by ex vivo respiratory tract organ culture. 
Influenza Other Respir Viruses. 2013;7(3):393-402.
 13. van den Brand JM, Kreijtz JH, Bodewes R, et al. Efficacy of vac-
cination with different combinations of MF59-adjuvanted and 
nonadjuvanted seasonal and pandemic influenza vaccines against 
pandemic H1N1 (2009) influenza virus infection in ferrets. J Virol. 
2012;85(6):2851-2858.
 14. de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, 
Osterhaus AD. Haemagglutination-inhibiting antibody to influenza 
virus. Dev Biol. 2003;115:63-73.
 15. Potter CW, Oxford JS. Determinants of immunity to influenza in-
fection in man. Br Med Bull. 1979;35(1):69-75.
 16. Sun Y, Bian C, Xu K, et al. Immune protection induced on day 10 
following administration of the 2009 A/H1N1 pandemic influenza 
vaccine. PLoS One. 2010;5(12):e14270.
 17. Vesikari T, Richardus JH, Berglund J, et al. Immunogenicity and 
safety of a trivalent inactivated influenza vaccine in children 6 
12  |     VIDAÑA et Al.
months to 17 years of age, previously vaccinated with an AS03-
Adjuvanted A(H1N1)Pdm09 vaccine: two open-label, randomized 
trials. Pediatr Infect Dis J. 2015;34(7):774-782.
 18. Ann J, Samant M, Rheaume C, et al. Adjuvanted inactivated influ-
enza A(H3N2) vaccines induce stronger immunogenicity in mice 
and confer higher protection in ferrets than unadjuvanted inacti-
vated vaccines. Vaccine. 2014;32(43):5730-5739.
 19. Baras B, de Waal L, Stittelaar KJ, et al. Pandemic H1N1 vaccine re-
quires the use of an adjuvant to protect against challenge in naive 
ferrets. Vaccine. 2011;29(11):2120-2126.
 20. van den Brand JM, Stittelaar KJ, van Amerongen G, et al. 
Comparison of temporal and spatial dynamics of seasonal H3N2, 
pandemic H1N1 and highly pathogenic avian influenza H5N1 virus 
infections in ferrets. PLoS One. 2012;7(8):e42343.
 21. Keynan Y, Malik S, Fowke KR. The role of polymorphisms in 
host immune genes in determining the severity of respiratory ill-
ness caused by pandemic H1N1 influenza. Public Health Genom. 
2013;16(1-2):9-16.
 22. Horby P, Nguyen NY, Dunstan SJ, Baillie JK. The role of host ge-
netics in susceptibility to influenza: a systematic review. PLoS One. 
2012;7(3):e33180.
 23. To KK, Zhang AJ, Hung IF, et al. High titer and avidity of nonneu-
tralizing antibodies against influenza vaccine antigen are associated 
with severe influenza. Clin Vaccine Immunol. 2012;19(7):1012-1018.
 24. Ubol S, Halstead SB. How innate immune mechanisms contrib-
ute to antibody-enhanced viral infections. Clin Vaccine Immunol. 
2010;17(12):1829-1835.
 25. Skowronski DM, De Serres G, Crowcroft NS, et al. Association 
between the 2008–09 seasonal influenza vaccine and pandemic 
H1N1 illness during Spring-Summer 2009: four observational stud-
ies from Canada. PLoS Med. 2010;7(4):e1000258.
 26. Short KR, Kroeze EJ, Fouchier RA, Kuiken T. Pathogenesis of in-
fluenza-induced acute respiratory distress syndrome. Lancet Infect 
Dis. 2014;14(1):57-69.
 27. Vidana B, Martinez J, Martorell J, et al. Involvement of the different 
lung compartments in the pathogenesis of pH1N1 influenza virus 
infection in ferrets. Vet Res. 2016;47(1):113.
How to cite this article: Vidaña B, Brookes SM, Everett HE, 
et al. Inactivated pandemic 2009 H1N1 influenza A virus 
human vaccines have different efficacy after homologous 
challenge in the ferret model. Influenza Other Respi Viruses. 
2020;00:1–12. https://doi.org/10.1111/irv.12784
